Clinical trial
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic…
NCT00114244 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00114244 |
|---|---|
| Title | Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | A Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Pancreatic Cancer |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, gemcitabine hydrochloride, laboratory biomarker analysis |
| Enrollment | 52 |
| Start date | Dec 1, 2004 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Jun 14, 2005 |
| Last update posted | Jan 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: